SCHEMBL4327779

SCHEMBL4327779

COc1cc(Br)c(C2C3=CC=C4N=C(C)C=C4C3OC(N)=C2C#N)cc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
KDM4E B2RXH2 6/20 0.34
MAPT P10636 5/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
HPGD P15428 2/20 0.34
MYB P10242 4/20 0.34
HTT P42858 2/20 0.34
ALDH1A1 P00352 4/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
POLB P06746 2/20 0.33
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
USP7 Q93009 3/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4327691 0.84 MEN1 (0.42) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL4330028 0.84 TUBB4A (0.45) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL7539189 0.73 TUBB4A (0.44) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL4322216 0.69 TUBB4A (0.47) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL5959344 0.68 MAPT (0.45) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL4327990 0.66 NPC1 (0.45) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL4319313 0.63 TSHR (0.40) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL6640084 0.63 MYB (0.47) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL4426915 0.63 HSD17B10 (0.49) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL6642358 0.62 TUBB4A (0.44) MEN1KMT2AKDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507762-B2 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2009-03-24 US disclosed
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-07-14 US disclosed
US-6906203-B1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-06-14 US disclosed
EP-1230232-B1 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, CASP5 MEN1 2868/4885KMT2A 3138/4885KDM4E 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.